Literature DB >> 16480593

[Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma].

Dan Sha1, You-Jian He.   

Abstract

BACKGROUND &
OBJECTIVE: Vascular endothelial growth factor (VEGF) and its receptors fms-like tyrosine kinase-1 (Flt-1) and kinase insert domain containing receptor (KDR) play critical roles in angiogenesis and tumor progression. This study was to explore the correlations of VEGF, Flt-1 and KDR expression to clinical features and prognosis of nasopharyngeal carcinoma (NPC) patients.
METHODS: Immunohistochemistry was adopted to detect the expression of VEGF, Flt-1, and KDR in 127 specimens of NPC. SPSS statistical software was used to analyze their correlations to clinical features and prognosis of NPC patients.
RESULTS: The positive rates of VEGF,Flt-1,and KDR were 66.9%, 90.6%, and 88.2% in the NPC specimens. The expression of VEGF was positively related to the expression of Flt-1 and KDR (r=0.292, P<0.01; r=0.287, P<0.01). The expression of Flt-1 was positively related to the expression of KDR (r=0.723, P<0.01). VEGF expression was related to primary tumor site, lymph node metastasis, and clinical stage (P=0.04, P<0.01, P=0.02, respectively); KDR expression was related to primary tumor site (P=0.03); all of them were related to local recurrence and/or distal metastasis (P<0.01, P<0.01, P=0.01, respectively), and poor overall survival (P<0.01, P=0.01, P=0.03, respectively). Cox multivariate analysis showed age of more than 50 years and positive VEGF expression were independent prognostic factors (P<0.01, P<0.01).
CONCLUSION: VEGF, Flt-1, and KDR are widely expressed in NPC tissues, and are positively related to clinical features and prognosis of NPC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480593

Source DB:  PubMed          Journal:  Ai Zheng


  8 in total

1.  Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer.

Authors:  Linchun Wen; Rui Wang; Xiyan Lu; Chuanwen You
Journal:  Oncol Lett       Date:  2015-03-04       Impact factor: 2.967

2.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

Review 3.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress.

Authors:  William Chi-Shing Cho
Journal:  Mol Cancer       Date:  2007-01-02       Impact factor: 27.401

Review 4.  Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma.

Authors:  Wei Chen; Guo-Hua Hu
Journal:  Cancer Biol Med       Date:  2015-03       Impact factor: 4.248

5.  A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis.

Authors:  Feng Wang; Lisha Peng; Yong Wang; Xiaodong Liu
Journal:  Front Oncol       Date:  2018-10-31       Impact factor: 6.244

6.  Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model.

Authors:  Shanshan Liu; Fei Wu; Yanling Zhang; Rongsheng Qin; Nengping Zhu; Yuan Li; Mingting Wang; Qin Zeng; Danna Xie; Yinghua Li; Juan Fan; Yunwei Han
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

7.  Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma.

Authors:  Yu-Hong Li; Chun-Fang Hu; Qiong Shao; Ma-Yan Huang; Jing-Hui Hou; Dan Xie; Yi-Xin Zeng; Jian-Yong Shao
Journal:  J Transl Med       Date:  2008-01-03       Impact factor: 5.531

8.  Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.

Authors:  Cong Xue; Ying Tian; Jing Zhang; Yuanyuan Zhao; Jianhua Zhan; Wenfeng Fang; Li Zhang
Journal:  Drug Des Devel Ther       Date:  2016-03-15       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.